Game Your Game Inc. Launches Altus Sports Group Subsidiary
$GYGY · Game Your Game Inc.Research Summary
AI-generated summary of this SEC filing
Game Your Game Inc. Launches Altus Sports Group Subsidiary
What Happened
Game Your Game, Inc. (GYGY) announced on an 8-K that it formed and launched a new majority-owned subsidiary, Altus Sports Group, Inc. (ASG), effective August 24, 2026, to pursue sports talent representation, athlete branding and sports marketing. GYGY holds 70% of ASG’s common stock; four named founders—Michele Rinchiuso (ASG CEO), Mohammed Majid (CFO/COO), Ehsen Shah (Chief Strategy Officer) and Patryk Strojny (Advisor)—collectively hold the remaining 30%. The company agreed to provide ASG with initial funding of $200,000 and filed the Stockholders’ Agreement (Exhibit 10.1) and a press release announcing the launch (Exhibit 99.1).
Key Details
- Effective Date: August 24, 2026; press release filed August 25, 2026.
- Ownership: GYGY owns 70% of ASG common stock; Founders own 30%. Soumya Das (GYGY Chairman & CEO) is ASG’s sole director.
- Funding & vesting: GYGY committed $200,000 initial funding. Founder shares vest over four years (25% at 1 year, then monthly over 36 months), with forfeiture on termination and full vesting on certain change-of-control events.
- Governance and transfer rights: Stockholders’ Agreement includes Company approval rights, Founder consent requirements for certain actions while Founders hold ≥10%, first refusal rights (ASG then Company) on post-4-year transfers, and reciprocal drag‑along/tag‑along and purchase rights on change-of-control transactions.
Why It Matters
This filing shows GYGY is expanding into sports representation and marketing via a controlled subsidiary, which could create a new business line and future revenue opportunities. The Company retains majority ownership and control while aligning founder incentives through multi-year vesting and specified governance protections. The initial cash commitment ($200,000) is modest, so investors should watch for further capital infusions, operational updates, and any future transactions (equity issuances, sales or change-of-control events) that could affect valuation or dilution.